Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Portfolio Pulse from Vandana Singh
Gossamer Bio Inc (NASDAQ:GOSS) has partnered with Italy's Chiesi Farmaceutici to develop and commercialize seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The collaboration aims to advance lung health solutions globally, with both companies sharing development costs and commercial profits in the U.S. Chiesi will lead commercialization outside the U.S. and pay Gossamer up to $486 million in development, regulatory, and sales milestones.
May 06, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gossamer Bio's partnership with Chiesi Farmaceutici to develop and commercialize seralutinib represents a significant advancement in treating PAH and PH-ILD. The agreement includes a $160 million development reimbursement to Gossamer, up to $146 million in regulatory milestones, and $180 million in sales milestones, totaling up to $486 million.
The partnership with Chiesi not only provides Gossamer Bio with significant financial incentives but also leverages Chiesi's global commercialization capabilities, potentially accelerating seralutinib's market entry and adoption. The financial terms of the deal, including the development reimbursement and milestone payments, are likely to have a positive impact on Gossamer Bio's financial health and stock price in the short term, as reflected by the initial 1.26% increase in share price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100